Complete response after “neoadjuvant” pertuzumab + trastuzumab + docetaxel chemotherapy in Her2-positive breast cancer

It is well demonstrated that Her-2 positive breast cancer patients have more aggressive disease, with a poor prognosis. The author report the case of a 50-year-old Caucasian woman, diagnosed with a seven-centimeter right breast cancer. Biospy core revealed a Her-2 positive, positive for hormonal receptors, ki67 at 70%, breast invasive ductal carcinoma, associated with right axillary adenomegalies. Positron emission tomography scan showed diffuse metastatic adenomegalies upper and under the diaphragm and a 55×55 mm lesion in the right breast. The patient began chemotherapy with docetaxel+pertuzumab+trastuzumab regimen. After three courses, all the positron emission tomography scans did not show any pathological hypermetabolism and the primitive lesion was measured at 16×18 mm. It was decided to perform a right mastectomy. The patient will then follow maintenance with pertuzumab and trastuzumab, in combination with hormonotherapy.

Her2 breast cancer; Pertuzumab; Metastatic breast cancer; Her2-targeted therapies.

[1] Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N.: “The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine”. Oncologist, 2009, 14, 320.

[2] Chia S.K., Speers C.H., D’yachkova Y., Kang A., Malfair-Taylor S., Barnett J., et al.: “The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer”. Cancer, 2007, 110, 973.

[3] Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al.: “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2”. N. Engl. J. Med., 2001, 344, 783

[4] Rapiti E., Verkooijen H.M., Vlastos G., Fioretta G., Neyroud-Caspar I., Sappino A.P., et al: “Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis”. J. Clin. Oncol., 2006, 24, 2743,

[5] Khan S.A., Stewart A.K., Morrow M.: “Does aggressive local therapy improve survival in metastatic breast cancer?” Surgery, 2002, 132, 620.